EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An evidence‑based framework for molecular test selection in oncology: comparing targeted NGS panels and comprehensive sequencing

Kanako Okamoto, Anthony Garcia, James Cole, Sammy Kanugo, Jon Fretthold, Shuko Harada, Darshan Shimoga-Chandrashekar, A. Craig Mackinnon

Precision Pathology · 2026

DOI: 10.1016/j.prpath.2026.100003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Precision Pathology, 2026. Verfasst von Kanako Okamoto und 7 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted next‑generation sequencing (NGS) panels are widely used in clinical oncology, yet their efficiency relative to comprehensive profiling by whole‑exome and whole‑transcriptome sequencing (WES/WTS) for therapeutic decision‑making and clinical trial enrollment remains uncertain. We evaluated the clinical impact of targeted panels versus WES/WTS across multiple tumor types using AMP/ASCO/CAP variant tiering and an institutional trial‑matching framework. We analyzed 1,306 clinical reports comprising 6,712 variants, resulting in 4,892 unique variants after deduplication. All alterations were tiered per AMP/ASCO/CAP guidelines, with emphasis on therapeutically relevant Tier IA/IB and Tier IIC variants. Coverage of these variants by commercially available 50‑gene, 505‑gene, and fusion gene targeted panels was assessed across eight cancer types. To evaluate downstream clinical impact, we developed an algorithm to match 1,141 patients who underwent WES/WTS to biomarker‑driven clinical trials actively enrolling at our institution between July 2019 and August 2024 and compared trial eligibility outcomes using targeted panels with those from WES/WTS. Overall, 2,456 unique Tier I, II, or III variants were identified, including 130 Tier IA/IB variants (2.65% of all unique variants). The proportion of Tier I alterations varied by cancer type, with breast cancer showing the highest (11.2%) and endometrial cancer the lowest (0.4%). A subset of clinically relevant Tier IA/IB and IIC variants detected by WES/WTS was not covered by targeted panels, ranging from 6 variants in pancreatic cancer to 52 variants in brain and endometrial cancers. In trial‑matching analyses, targeted panels achieved full concordance with WES/WTS in 39.9% of patients, while 11.7% were eliminated from potential trials due to a lack of biomarker coverage. Concordance was highest for pancreatic (98.4%) and colorectal (91.7%) cancers, whereas substantial proportions of ovarian, soft tissue sarcoma, breast cancer, and glioblastoma patients were excluded from biomarker‑driven trials when relying on targeted panels alone. Targeted NGS panels provide clinically actionable information comparable to WES/WTS for most common tumor types when treatment decisions rely primarily on established Tier IA/IB biomarkers. However, comprehensive WES/WTS profiling remains critical for tumors with complex genomic landscapes and for maximizing access to biomarker‑driven clinical trials. A stratified testing strategy deploying targeted panels for routine care while reserving WES/WTS for select clinical contexts offers a pragmatic balance between precision oncology goals and responsible resource utilization.

Zitieren

APA

Okamoto, K., Garcia, A., Cole, J., Kanugo, S., Fretthold, J., Harada, S., Shimoga-Chandrashekar, D., & Mackinnon, A. C. (2026). An evidence‑based framework for molecular test selection in oncology: comparing targeted NGS panels and comprehensive sequencing. Precision Pathology. https://doi.org/10.1016/j.prpath.2026.100003

Vancouver

Okamoto K, Garcia A, Cole J, Kanugo S, Fretthold J, Harada S, et al. An evidence‑based framework for molecular test selection in oncology: comparing targeted NGS panels and comprehensive sequencing. Precision Pathology. 2026. doi:10.1016/j.prpath.2026.100003

BibTeX
@article{Okamoto2026,
  author = {Okamoto, Kanako and Garcia, Anthony and Cole, James and Kanugo, Sammy and Fretthold, Jon and Harada, Shuko and Shimoga-Chandrashekar, Darshan and Mackinnon, A. Craig},
  title = {An evidence‑based framework for molecular test selection in oncology: comparing targeted NGS panels and comprehensive sequencing},
  journal = {Precision Pathology},
  year = {2026},
  doi = {10.1016/j.prpath.2026.100003}
}
Kostenlos starten →